MAP2K7 and melanoma: Similarly, Maertens and colleagues demonstrated that both RAF and MEK inhibitor sensitive and resistant melanoma can be effectively treated with a combination of RAF/MEK inhibitors and the HDAC3 inhibitor entinostat [201].